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ABSTRACT

Human and animal populations are experiencing a rapid increase in
exposure to potential environmental toxicants in the form of pharmaceutical

drugs, commercial chemicals, industrial by-products, wastes and recreational

drugs not properly tested. These agents can cause birth defects directly by
interfering with embryogenesis. Tobacco products (TPs) are known toxicants

which can cause birth defects and are implicated in adult bone disorders and are

known to generate reactive oxygen species (ROS). ROS are also associated with
disorders including ageing and osteoporosis. However, it is unknown how TP-

induced ROS modulates pathways important for embryonic skeletal

development. Human embryonic stem cells (hESCs) are a developmentally
powerful model of embryonic development, including skeletogenesis. They have

a self renewal property and are capable of differentiating into cell types of three
germ layers, including the bone forming osteoblasts. Here, hESCs of the line H9
were induced into osteoblasts to examine osteotoxicity in the presence of TPs.

When osteogenic cultures were treated with non-effective (0.01%) and effective

doses (0.1%) of snus tobacco extracts (STE), 0.1% STE exhibited inhibition of
calcification without a cytotoxic effect. In addition, a higher yield of ROS, O2- and
H2O2, were detected in the effective dose. Furthermore, the levels of superoxide
dismutase and catalase, free scavenging enzymes that remove ROS, were

decreased. Taken together, these data indicate a possible inability of
differentiating hESCs to counteract the high levels of ROS which correlates with

iii

their inability to continue osteogenesis. Therefore, STE-induced ROS may be an

underlying cause of skeletal teratogenicity.
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CHAPTER ONE
INTRODUCTION

Adverse Effects of Tobacco Exposure
Tobacco smoke harms nearly every organ in the body. In general, tobacco

reduces the overall health of the user.1 Tobacco smoke, composed of
mainstream smoke, which is inhaled by the smoker, (MS) and sidestream (SS)

smoke, which burns off the tip of the cigarette,2 is a common environmental
toxicant and is the single most preventable cause of disease, disability, and

death in the United States.3 The Center for Disease Control (CDC) has estimated

nearly 500,000 people die every year due to tobacco-related diseases and

another 8.6 million live with a serious illness caused by smoking.1 Cigarette
smoke is a mixture of over 4500 toxic components with at least 69 smoke
chemicals that produce cancers, undeniable evidence that smoking Is harmful to

smokers.4,5 The leading cause of cancer of both men and women in the United
States, cigarette smoking causes many types of cancer such as cancers of the

lung, esophagus, larynx, mouth, throat, kidney, bladder, pancreas, stomach,
cervix and acute myeloid leukemia.6 Through in vivo studies, skeletal diseases
have been linked to cigarette smoke. Smokers have 4-5% lower bone mineral

density (BMD) values than non-smokers, a higher rate of pseudarthrosis in the
lumbar spine after surgery, delayed healing of fractures and callus formation, and
are at an increased risk of developing osteoporosis.5 More importantly, the World

1

Health Organization (WHO) has estimated that 10% of the world population is

involuntarily exposed to environmental smoke,3 a number that does not include

developing embryos. Despite the worldwide knowledge of the health related risks
for adults, approximately 46.6 million U.S. citizens continue to smoke cigarettes.3
While it was previously believed that cigarette smoke only affected the
active smoker, in the early 1980’s it was concluded that mothers, developing

embryos and children are also susceptible to the adverse affects of tobacco due
to exposure to environmental tobacco smoke.7 It is estimated that 25% of women
in the United States smoke during pregnancy,8 and pregnancy represents a

period of human development in which the embryo is particularly susceptible to
toxins in tobacco smoke because of high cell proliferation, organ development
and the changing capabilities of fetal metabolism.7 Exposure to tobacco smoke
increases the mother’s risk of spontaneous abortion, premature delivery, infertility

and fetal abnormalities such as long-term effects on brain function and cognition,
improper development of the skeleton, and risk of fetal mortality and morbidity.6,9

Moreover, nicotine exposure has shown toxicological effects on

neurodevelopment including motor, sensory, and cognitive loss.7 While it is
known that tobacco products have detrimental effects on adult bone tissue

(Figure 1) and tobacco affects both smokers and nonsmokers, little is known
about the effects of tobacco products on bone development and fetal response to
increasing levels. Because developing embryos and children are involuntarily
exposed to tobacco smoke, it is therefore important to elucidate the mechanisms

2

behind the adverse effects of tobacco smoke on the developing embryo to
provide the ground work for potential congenital abnormality related research.

3

Group 1
(0 riigZJL)

Group 4
(50 mg7L)

Figure 1. Nicotine Affects Bone Regeneration. Nicotine
administered to rats after parietal grafting surgery
hindered bone regeneration. Arrow points to
regeneration of bone in non-nicotine treated tissue.
Parietal bones were removed from one side of the
skull and transplanted to the other side in rats exposed
to nicotine or non- treated controls. Hollinger JO,
Schmitt JM, Hwang K, Soleymani P, Buck D. 1999.
Impact of nicotine on bone healing. Journal of
Biomedical Materials Research. 45(4):294-301.
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Developmental Toxicology

Developmental toxicology defines the adverse effects of deleterious
agents on development processes, from the period of fertilization, to the
transformation of the egg into embryonic germ layers, organogenesis, and
embryonic and fetal growth. The development of an organism occurs in a short

amount of time, therefore, any compound exposed to the developing organism

during pregnancy may perturb development. The unfavorable effects on
development, growth or behavior are due to environmental factors such as drugs,
alcohol, diet, lifestyle, and environmental chemicals. Human and animal

populations are experiencing a rapid increase in exposure to potential
environmental toxicants in the form of pharmaceutical drugs, commercial

chemicals, industrial by-products, wastes and a number of drugs not properly

tested. In the United States, over 1500 new compounds enter the environment
each year.11 These agents can cause birth defects directly by interfering with
embryogenesis. The thalomide disaster in the early 1960’s established the need

for studies on developmental toxicity when pregnant women taking the drug and

doctors discovered the teratogenicity of thalomide. This demonstrated the need
to identify and predict the developmental toxicity of putative toxicants prior to

being released into the environment or for human use.
Bone is a crucial vertebrate organ that provides support, protection,
storage of minerals, and produces red and white blood cells. A variety of
signaling pathways, such as the Wnt/CatnB signaling pathway, and regulatory
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factors (transcription factors, hormones, growth factors, and cytokines) controls

the development of bone tissue. Prenatal exposure to potential environmental
toxicants can interfere with signaling pathways and regulatory factors of bone

development and result in congenital bone abnormalities, such as limb
malformations. According to the CDC, one in every 33 infants in the United

States are bom with a birth defect, and birth defects are the cause of 1 out of
every 5 infant deaths, making them the leading cause of deaths today.12

Environmental, or genetic factors, or the combination of the two acting together

have been estimated to be the majority cause of birth defects.13 Despite this
knowledge, many environmental agents and the mechanisms by which they
cause developmental toxicity remains poorly understood.13
Embryotoxicitv Tests

Toxicity screenings were first used to determine the minimal dose of

tobacco smoke necessary to produce adverse effects on development.14 The
majority of toxicity screening was done using laboratory animal models.

However, animal models require a large amount of resources, are time
consuming, and are costly. While in vivo models do demonstrate the adverse

effects of chemicals, such as tobacco products, on development, however, these
models do not accurately demonstrate the dose response adverse effects.14,15 In

the 1980’s, efforts to detect embryotoxic agents were implemented by the

Organization for Economic Co-operation and Development (OECD). However,
these methods proved to be time-consuming, costly, and raised ethical concerns

6

due to large amounts of animal testing. Moreover, animal responses to toxicants
do not always accurately parallel human responses to the same compound. The

use of in vitro testing is necessary to sufficiently screen for the adverse affects of
compounds present and newly entering the environment.

To circumvent traditional methods of embryotoxicity testing, various in
vitro alternatives have been introduced. Widely used by industry, the MicromassTest, whole embryo culture (WEC), and Frog Embryo Teratogenesis Assay

Xenopus (FETAX) test are labor intensive assays but carry a predictive value
between 70% and 80%.16,17 Spielmann et al.,18 described the cell based test that

is validated as an alternative model, the embryonic stem cell test (EST). Though

the test abrogates the use of animal testing, the endpoints are prone to error.
The EST is based on three endpoints: (1) cell differentiation: inhibition of ESC
differentiation into cardiomyocytes, assessed by light microscopy; (2) cell
viability: inhibition of 3T3 and ESC viability assessed by the MTT assay (ID50);

and (3) cell proliferation: inhibition of 3T3 and ESC proliferation (IC50).19
However, these methods of assessment are problematic. The test is based on

the differentiation into one cell type, a limitation if tissues respond differently to
different chemicals. The length of time of the assay, 10 days is too long for

toxicity screening and the ability to detect beating cardiomyocytes requires

patience and trained personnel. Based on reports of disadvantages such as
these, the endpoints of the EST are continuously being improved. Efforts to

improve efficiency of the EST have resulted in shortening the assay to 7 days

7

and development of a promising new FACS and quantitative PCR based
embryotoxicity testing platform.20,21

Due to the serious risks environmental agents pose to embryonic
development it is vital to develop novel approaches for understanding and

predicting toxicity and toxicants in vitro. The EST is one of few tests available to
study the effects of agents on skeletal development.22 Due to limitations of the

EST cardiogenic endpoints and the fact that most developmental toxicants result

in limb, skeletal, or CNS malformations,21 it would be beneficial to differentiate
embryonic stem cells (ESCs) into other lineages that can be easily tested with

the EST to identify developmental toxicity.21 In 2011, zur Nieden et al. utilized the
EST to determine developmental osteotoxicity of chlorides in mouse ESCs

(mESCs).22 Using their osteogenic induction protocol, mouse embryoid bodies
(EBs) were differentiated into mineralized osteoblasts and the toxicity of NaCl,
UCI, MgCfe and AICI3 on bone development was determined using the EST.

However, mouse models do not always provide an accurate account for human
developmental toxicity, requiring the use of human ESCs (hESCs) to mimic the
developmental toxicity of human embryos.

Embryonic stem cells are a powerful tool for studying development and

cell lineage commitment because they are able to undergo differentiation into any
cell type, including bone-forming osteoblasts. In addition, hESC lines can be

utilized in toxicity assays to identify and predict the teratogenicity of a given
compound. Moreover, hESCs are a great tool for elucidating how embryonic and

8

fetal life can be disrupted when exposed to tobacco products and result in bone
disabilities.

Stem Cells
Stem Cell Research

In recent years, scientific understanding of stem cells has greatly
expanded the fields of developmental, molecular, toxicological, and cancer
biology. While some view stem cells as a relatively new finding, the term was

actually used as far back as the beginning of the 19thcentury. Alexander
Maksimov a Russian histologist coined the term “stem cell” in 1908 when he
hypothesized the process of hematopoiesis.23 Nearly 60 years later, Joseph
Altman.24,25 provided evidence of neurogenesis in adult rat brains from constant

‘undifferentiated cell’ activity, demonstrating the existence of pluripotent cells.
Moreover in 1963, McCulloch et al.,26 illustrated pluripotent stem cell’s capacity to

self renew, proliferate extensively, and to differentiate. Then in 1998, the modern
era of stem cell research began with the derivation of hESCs by Thomson et al.

This groundbreaking work changed the landscape of human cell developmental
biology by giving scientists the first actual in vitro model of non-transformed
human cells.27 Using stem cells, researchers were able to tackle the mysteries of

differentiation via an inexpensive in vitro model that is similar to in vivo growth.

Since ESCs differentiate into the cells that become all 3 germ layers, researchers

have the potential to manipulate and study differentiation at the earliest stages of

9

life, such as gastrulation.28 As developmental biologists begin to paint a clearer

picture of what is happening during the first stages of life, they are able to shed

light on many of the problems facing medicine today.29 Potential application of
stem cells other than toxicology include renewing and replacing damaged cells
and tissues due to diseases and injuries such as heart disease, arthritis, spinal
cord injury, and bums.

Stem Cell Types
Embryonic Stem Cells, In culture, ESCs survive in compact colonies.

Individually, they have a high nuclear to cytoplasmic ratio and posses multiple
nuclei. ESCs are pluripotent cells derived from the inner cell mass of a

blastocyst. hESC lines are typically obtained from cryopreserved human embryos
that are discarded during in vitro fertilization.27 They can maintain pluripotency for

prolonged periods in vitro.28 Furthermore, ESCs have the ability to undergo

sustained proliferation and are able to differentiate and give rise to all three germ

layers and thus all cells of the body (Figure 2).

ESC pluripotency and proliferation is attributed to the expression of stage
specific pluripotency markers and high telomerase activity. hESCs express Oct-

3/4, NANOG, Sox2, (SSEA)-3, and SSEA-4 to maintain pluripotency and the
downregulation of these genes is associated with the start of differentiation. The

prolonged lifespan of ESCs is associated with increased telomerase expression,
which is low in somatic cells,27 leading to telomere length being maintained.
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For hESCs to differentiate towards a specific lineage, expression of

pluripotency markers must be suppressed. ESCs progressing towards a
particular lineage first produce a daughter cell and a progenitor cell, in an

asymmetrical division.30 Progenitor cells undergo a limited number of divisions (a

distinction from ESCs) before terminally differentiating into a mature cell.31 Due to
this ability to propagate themselves indefinitely, ESCs are a developmentally
powerful tool for developmental toxicology research and regenerative medicine.

However, embryonic stem cell research is a controversial issue. Obtaining
hESCs requires the destruction of a 5 day old human embryo to obtain the cells

from the inner cell mass of a blastocyst, thus discontinuing human development.
The use of stem cells has boosted the pro-life movement, where their supporters

consider that embryos have rights and are "young” humans.

Adult Stem Cells. Unlike ESCs, adult stem cells (ASCs) are
undifferentiated cells derived from specific tissues and are not pluripotent.
Though identical to their parent tissue type, these cells are only able to
differentiate into the cell type of the tissue they originated from. The nature of

ASCs is to maintain and repair the tissues that they come from. ASCs have been
identified in many tissues and are named according to where they originate from,

such as mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs),
neural stem cells (NSCs), and epithelial stem cells (Epi-SCs). Specifically, HSCs

and MSCs have been used therapeutically for decades,32 such as for

11

regeneration of blood and bone. Since ASCs are derived from mature tissues,

they do not carry the same ethical concerns as ESCs.
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Totipotent

Embryonic Stem Celis

I
Neural .cells

Cardiac muscle

Figure 2. Embryonic Stem Ceil Derivation and Differentiation.
Totipotent cells (zygote), can form all types of cells including the
organism and the trophoblast. Pluripotent human embryonic stem
cells (hESCs) are derived from the inner cell mass of the blastocyststaged embryo and can form all three germ layers, but not the extra
embryonic structures. Landry DW, Zucker HA. 2004. Embryonic
death and the creation of human embryonic stem cells. JournaLof
.Clinical Investigation. 114(9):1184-1186.
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Induced Pluripotent Stem Cells. Through the nuclear reprogramming of
somatic cells, stem cells can be generated. Takahashi and Yamanaka34 first

created induced pluripotent stem cells (iPSCs) in 2006 by retrovirally introducing

four factors, Oct3/4, Sox2, c-Myc, and Klf4 into mouse fibroblasts. A year later,
Takahashi et al.35 reprogrammed human somatic cells to a pluripotent state
(hiPSCs) utilizing the same four factors. These cells are similar to hESCs

morphologically, express ESC surface markers, and express telomerase. Due to
c-Myc’s ability to cause cancer, further research has determined other factors
that can also be used to reprogram human somatic cells. In 2007, Thomson et
al.36 demonstrated that Oct3/4, Sox2, NANOG, and LIN28 were sufficient to

induce pluripotency in human somatic cells and create stem cells that resemble

hESCs.
The ability to generate pluripotent cells holds great potential in patient
specific cell-based therapies, and removes the ethical controversy that hESCs

posses. hiPSCs are created from adult cells, avoiding destruction of blastocysts,

and can determine an individual’s response to any given toxicant (Figure 3).
Cell Culture

Both hESCs and hiPSCs need specific culture conditions to maintain
pluripotency. Originally, hESCs were maintained on mouse embryonic fibroblast

(MEF) feeder cells in culture medium with fetal bovine serum (FBS).27 However,
culturing with FBS is problematic due to unknown components that vary from

batch to batch. To minimize the possible adverse effects of this complication,

14

laboratories typically order significant amounts of a particular lot of FBS once

they have found a suitable one. In addition, the use of MEFs are not ideal for
research settings due to animal contamination. In efforts to avoid feeder
dependent systems, the ability to culture pluripotent hESCs on feeder-free

systems was made commercially available with Matrigel, a gelatinous mixture
including lamina, collagen IV, and enactin secreted by Engelbreth-Holm-Swarm

(EHS), a mouse sarcoma cell, that resembles the complex extracellular
environment (BD Biosciences).

In addition to the constraints of FBS and feeder layers, passaging of
hESCs is a laborious process. Unlike mESCs that can be enzymatically

dissociated into single cells,, hESCs must remain in clumps to prevent karyotypic
changes and avoid cell death.37 Passaging hESCs in small colonies is done

mechanically with the use of a cell scraper or glass beads and application of an

enzyme, such as accutase, to lift cells off the substrate.
Summary

Human pluripotent stem cells’ in vitro capacity makes them an attractive
alternative to determine the potential adverse effects of toxic agents on humans.

Since they are able to repeat embryonic development and express tissue-specific
markers, hESCs and hiPSCs are adequate tools to assess developmental

toxicity. With cardiotoxicity models established, the EST with limitations (reported
earlier), this study demonstrates in vitro osteotoxicity due to snus chewing

tobacco.
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Figure 3. Induced Pluripotent Stem Cell Differentiation.
Induced pluripotent cells (iPSCs).are pluripotent and are
derived from human somatic cells by reprogramming with
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and induced pluripotent stem cells; [cited 2010 Apr
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Plqmoni
Cell

Osteogenesis
Skeletal development is a process initiated by condensations of

mesenchymal precursor cells that will result in the formation of bone. The
vertebrate skeleton is mainly comprised of bone; the two major cell types in bone
are osteoblasts, which function in bone formation, and osteoclasts, that operate
in bone resorption. Bone arises from mesoderm or from ectoderm via neural

crest.39 During bone mineralization, bone tissue has the ability to become
calcified via osteoblasts mineralizing osteoid, its uncalcified precursor.39

Researchers have developed in vitro protocols that differentiate ESCs into

functionally mineralizing osteoblasts in the extracellular matrix (ECM), a hallmark
of bone formation.40,41
Bone Development

Differentiated from MSCs, osteoblasts are mature cells. Osteoblast

differentiation is controlled by stage (proliferation, differentiation, mineralization,

and maturation) specific expression of regulatory proteins. Factors that control
osteoblastogenesis include alkaline phosphatase (ALP), core binding factor

alpha 1 (Cbfal), osteopontin (OPN), bone sialoprotien (BSP), and osteocalcin
(OCN)42,43

One of the earliest and necessary signaling pathways in almost every

aspect of embryonic development is the Wnt signaling pathway.44 This pathway
is known to have a role in determining the switch from proliferation to
differentiation. The Wnt family ligands are highly conserved glycoproteins
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implicated in many processes, such as cell migration, proliferation and the

regeneration of adult tissues.45 In the absence of Wnt signal, glycogen synthase
kinase 3p (GSK3p) forms a complex with axin, casein kinase 1, and
adenomatous polyposis coli (APC) which phosphorylates beta-catenin (CatnB)

and triggers ubiquitination, which leads to degradation of cytoplasmic CatnB.46,47
In the presence of Wnt, membrane bound receptors Frizzled (FZD) and lowdensity lipoprotein related protein 5/6 (LRP5/6) bind to Wnt which activates
Dishevelled (Dsh) to inhibit the GSK30 complex and promotes a limited pool of
cytoplasmic CatnB. Stable CatnB then translocates into the nucleus arid binds to

transcription factors of the lymphoid enhancer factor (LEF)/T cell factor (TCF)

family to activate specific Wnt target genes.45'47 The Wnt/CatnB pathway is also
indicated as the canonical Wnt pathway, in turn non-canonical Wnts do not signal
through CatnB and may suppress CatnB activity (Figure 4).45
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CANONICAL PATHWAY

PLANAR CELL POLARITY PATHWAY

WNT/Ca** PATHWAY

Figure 4. Canonical and Noncanonical Writ Signaling
Pathways. Wnt signaling transduction pathways are
categorized into canonical (CatnB pathway) and
noncanonical. the noncanonical pathways include
the Wnt/Ca2+ pathway and the Wnt/pianar cell
polarity pathway, which involve the downstream
members calmodulin kinase II (Cam-Kll), protein
kihaseC(PKC) and c-jun kinase (JNK):. Davis LA, zur
Nieden Nl. 2008. Mesodermal fate decisions of a
stem cell: the wnt switch. Cell and Molecular Life
Science. 65(17):2658-2674.
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Though incompletely understood, it is the stage specific control of canonical Writ
signaling that directs ESCs towards.mesoderm, endoderm, and primitive streak
cell fates. Davidson et al.,—found application of exogenous Wnt3a changed
hESC morphology and promoted differentiation. Moreover, qPCR data showed
that Wnt3a induced lineage specific: differentiation gene expression. During

osteogenesis, nuclear activity of CatnB specifically regulates neural crest
migration/specification as well as the'lineage-specification of mesenchymal

osteoprogenitors into mature osteoblasts (Figure 5)—essential for
differentiation.30'43,40,47
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Beta-Catenin. The upregulation and downregulation of nuclear
CatnB activity regulates stem cell lineage commitment. Davis LA,
zur NiederiiNI. 2008. Mesodermal fate decisions of a stem cell: the
wnt.switch. Cell and Molecular Life Science. 65(17):2658-2674.
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In vitro Differentiation. A great deal of research is focused on developing
in vitro techniques that allow hESCs to differentiate into homogenous cell types

for clinical purposes.49'50 Generation of somatic cells from hESCs is a potential
source of material for cell based therapies, more specifically, stem cells can be

used to predict a chemicals toxicity as well as identify how tissues respond to any

given chemical. Through the use of mESCs and manipulation of culture

conditions to direct differentiation towards lineage-specific pathways, many
protocols have been developed to generate numerous cell types, including

osteoblasts.39,40 Without the presence of leukemia inhibitory factor (LIF), a factor

used to maintain pluripotency, mESCs form distinct cellular aggregates or EBSi

which contain differentiating cells of all three germ layers.40,51 EBs provide an
efficient method for mimicking the 3D in vivo environment of ESCs in vitro.

mESCs are easily able to form EBs through various methods including

suspension (easiest method)51 and hanging drops (consistent size).19 The latter
method uses the exact number of cells within a drop of media, which the cells

aggregate within the drop. Though achievable, hESC EB formation creates
clumps of cells variable in size and morphology,52,53 and for experimental

purposes this can affect the results and robustness of the experiment.
Additionally, mESCs can survive as single cells which is beneficial when trying to

generate EBs that are similar in size and morphologically, whereas hESCs

neither remain pluripotent nor survive in a single cell state, thus requiring the
formation of EBs from clumps of hESCs.
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During osteogenesis, ascorbic acid and p- glycerophosphate (source of

organic phosphate) were determined necessary to provide an alkaline

environment which drives cells to secrete a mineralized matrix.29,39,54 Buttery et
al.40 showed that dexamethasone, p-glycerophosphate, and ascorbic acid
combined are sufficient to promote mESC osteogenic differentiation. Then zur

Nieden et al. enhanced osteoblast yield by coupling 1a,25 (OH)2 vitamin D3 with
ascorbic acid and p- glycerophosphate to trigger mESC expression of specific

bone marker genes.39,43. In addition, this method shortens the first onset of

osteoblasts from 4 weeks40 to 10 days and assessments of all osteogenic
markers are observable within a 20-30 day differentiation

Karp et al. enhanced osteoblast yield in hESC differentiation by removing

the difficult EB formation step along with the Buttery induction factors.55 In efforts

to differentiate hESCs in a reproducible manner, Vallier et al49,50developed a
method for differentiating hESCs through an overgrowth approach. The
overgrowth approach allows hESC colonies to remain in their initial seeding

positions and continue to proliferate (overgrow) past confluency coupled with
media to direct differentiation. The zur Nieden lab has pioneered hESC

osteogenic differentiation by enhancing methods that were developed to
differentiate murine ESCs into osteoblasts and chondrocytes in culture.39,42 The

zur Nieden lab omitted the EB step (which can result in a higher heterogeneous
culture) and added 1a,25 (OH)2 vitamin D3, ascorbic acid, and p-

glycerophosphate to hESC cultures. Utilizing this enhanced osteogenic method
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results in a higher yield of osteoblasts than previous methods, and osteoblasts
exhibit the in vivo hallmark of mineralization in the ECM. When ESCs undergo
differentiation into specific cell types, it requires a source of energy in order to do

so.

Mitochondrial Activity
Oxidative Stress

A broad spectrum of congenital brain abnormalities has been linked to
modification of mitochondrial oxidative phosphorylation (OXPHOS) and the
consequent generation of reactive oxygen species (ROS), resulting in oxidative

stress, due to environmental chemicals.56 Within mammalian cells, mitochondria
are a key source of ROS and play an important role in cell viability and cell death.

It is during OXPHOS that intracellular ROS, highly reactive molecules containing
oxygen and a single unpaired electron, is generated in an unavoidable event.57-62

Generation of ROS influences cellular processes and has been linked to

embryotoxicity and teratogenesis, aging, and the development of age-related
diseases, including neurological disorders.62,63 The primary ROS that leaks
during OXPHOS is superoxide anion (O2*"). The excessive generation of ROS

can have detrimental effects on cellular activity and structures, and this process
is termed oxidative stress.64 Oxidative stress occurs when ROS production
exceeds the cell’s natural antioxidant capacity, and the magnitude of the
imbalance determines the severity of the effects.61,63-65 ROS can also lead to
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oxidative damage of mtDNA and impair mitochondrial metabolic functions (Figure
6). Mutations and metabolic responses to environmental factors can generate

high levels of ROS,60 and excessive ROS can be devastating to the cellular
environment and the organism as a whole. However, moderate levels of ROS are
crucial for development because of their important contribution to cellular
signaling and cellular fate commitment.65
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mitochondrion

Figure 6. Mitochondrial Reactive Oxygen Species
Production. The production bf ROS via mitochondria
may result in oxidative damage to proteins;
membranes, and DNA. This can result in inhibition of
ATP synthesis and other mitochondrial functions.
Furthermore, oxidative damage can lead to the leaking
of cytochrome (cyt c) and activation Of apoptosis
pathways, and these responses are implicated in
multiple diseases. Murphy MP. 2009. How mitochondria
produce reactive oxygen species. Biochemical Journal.
417:1-13.
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Generation of Reactive Oxygen Species. Superoxide anion is the primary
ROS generated during aerobic respiration, however hydrogen peroxide (H2O2)

production was observed in pigeon heart mitochondria in 1971.59,64 It was this
observation that uncovered the dismutation of O2*“ into H2O2. One hallmark of

ROS (except H2O2) is the existence of one or more unpaired electrons. O2’“ is
generated when O2 is reduced by one electron, followed by the dismutation of

O2‘" to form H2O2 or the Fenton reaction to generate the hydroxyl radical (*OH)
(Figure 7). H2O2 is the most stable ROS and it is further converted to H2O and

O2. Cells have their own defense mechanisms that dismutates O2’“ and converts
it to H2O2. Located inside the mitochondrial matrix, manganese superoxide

dismutase’s (MnSOD) dismutates O2*“ into H2O2, and in turn, catalase and
glutathione peroxidase breaks down H2O2 to water and molecular oxygen, which

MnSOD and catalase are regulated by the same transcription factor.57,59'61,66
Forkhead Box-0 Family
The Forkhead box-O (FoxO) family of transcription factors plays a role in

helping cells to thwart the consequences of oxidative stress,67 and functions in
apoptosis and cell proliferation. In mammals, this family comprises four
members: FoxO1, FoxO3a, FoxO4 and FoxO6 and in response to oxidative

stress they induce cell arrest and quiescence.64,67,68 FoxO1, FoxO3, and FoxO4

show broad, overlapping patterns of expression in developing and adult tissues,
whereas FoxO6 is restricted to specific structures of the developing brain.69
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Drosophila melanogaster and Caenorhabditis elegans studies first identified

FoxO and named dFOXO and DAF-16 respectively.68'70

H2O2
NO

* h2o + 02

Fenton reaction
V

ONOO-

iOH

Figure 7. Sources of Reactive Oxygen Species. Superoxide anion (02* )
radical formed during OXPHOS is dismutated to form hydrogen
peroxide (H2O2) and further reduced to water and oxygen. When iron is
present in high concentrations, H2O2 can be spontaneously converted
to a highly reactive hydroxyl radical (’OH) via the Fenton reaction.
Reactive nitrogen species (RNS) include nitric oxide (NO*) and
peroxynitrite (ONOO-). Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y,
Kanematsu Y, Tamaki T. 2004. Atheroprotective effects of antioxidants
through inhibition of mitogen-activated protein kinases. Acta
Pharmacologica Sinica. 25(8):977-85.

27

Role of Forkhead Box-O. dFOXO and DAF-16 studies have shown that

these transcription'factors are controlled by the evolutionary conserved insulin-

phosphotidylinositol 3 kinase-protein kinase B (insulin-PI3K-PKB), which

promotes stress resistance and extended lifespan.68,70 Oxidative stress, heat and
starvation also stimulates DAF-16,68 suggesting that FoxOs have protective

capabilities.

l
Figure 8. Reactive Oxygen Species Mediated
Forkhead Box-0 Function. Superoxide dismutase
(SOD) and catalase remove damaging oxygen
species. When the ROS to radical scavenging enzyme .:
ratio is exceeded, oxidative stress will occur and have
detrimental effects.
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Reactive Oxygen Species Mediated Forkhead Box-0 regulation. Oxidative
stress results in shuttling of FoxOs into the nucleus and activation of transcription
by promoting FoxO posttranslational modifications, including phosphorylation,
ubiquitylation, and acetylation.52 ROS dependent FoxO activity is not completely

understood, however, modification enzymes such as JNK and MST1 bind to

FoxO after being triggered by ROS52,68,69 and FoxO nuclear localization and
activation is facilitated when it is phosphorylated by JNK and triggered by

oxidative stress (Figure 8).
Drosophila studies have provided evidence that the activation of dFOXO

has resulted in prolonging cellular life by way of JNK initiating the nuclear
translocation of dFOXO.69 In turn, nuclear FoxOs upregulate the transcription of

free radical scavenging enzymes (cellular defense enzymes) including MnSOD

and catalase to neutralize the effects of ROS 67,69 It is the evolutionary conserved
S1RT1 that deacetylates nuclear FoxO, which boosts the upregulation of
scavenging enzymes and quiescence.
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Aims and Objectives

The overall goal of this thesis project is to characterize the molecular

mechanisms of tobacco product induced skeletal teratogenicity. The hypothesis
that snus tobacco extract will increase the production of reactive oxygen species
(ROS) and in turn disrupts osteogenesis by altering signaling in the Wnt/p-

catenin pathway was investigated in respect to inhibition of osteogenic

differentiation by ROS. Specific objectives of this study were (Figure 9):

Specific aim 1: Determine whether hESCs or hiPSCs are suitable for this
project.

Specific aim 2: Determine whether tobacco products alter osteogenesis.
Specific aim 3: Determine whether tobacco products induce ROS, and, in
turn, if ROS affect osteogenesis.

Specific aim 4: Determine whether tobacco products alter FoxO activation.
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generation of intracellular ROS. Increased ROS will result in
oxidative stress which can upregulate apoptosis or activate the
cell’s defensive mechanism to counteract ROS and promote
longevity.
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CHAPTERTWO

MATERIALS AND METHODS

Materials

Table 1. List of Materials.
Materials
Media ............... '
;mTeSR®i
Control Differentiation Medium
Dulbecco's Modified Eagle's Medium (DMEM)
with L-gldamine.Glucose and NaHCO
T 5% Fetal Bovine Serum
1% NbrnEssential Arnind Acids;
1:200 penicillin/streptomydn
O.lmMB-mercaptoelhanol
VD3 Medium
Dulbecco’s Modified Eagle's. Medium (DMEM)

'

1

..
'■

.

with L-qlutamine,,Glucose and NaHCO
15% Fetal Bovine Serum
1% Non:Essential Amino Acids
1:200 penicillinfstreptomycin
0.1 rhM P-mercaptoeffianol

10mM; p-glycerophosphate

Atlanta
Gibco

1

.... _

Gibco ,
Sigma

...
1080
11140-035

!

15140-114
.M7522

..

i

; Gibed

Sigma
Sigma

i ’

419654)39

.

’
....

L

,

Galbiochem___________ _

.1080
111404)35
15140-1T4
M7522
A4403
679101
G9891
05855
356234

1

BD Biosdences
Sigma
_____ D2650
BioRad
, 500-0111
DCL. Toronto. Canada . ..
Sigma
t
A3469

substrate system for ELISA
.
PiPer™ Phosphate Assay Kit
LumiMax superoxide detection.kit
Dihydrorhodamirie-i 23

Molecular Probes
Agilent Technologies
Invitrogenl.
. ..

L

'

.....

NucleoSpiniRNAWkit
iQ™:SYBR®GreenSupefmix;,
.
NE-PER Nuclear and Cytoplasmic Extraction kit
SuperSignal West Pi co Chemilumi nescence
Protease Inhibitor ready, to .use1:100
Sodium Orthovanadate (100mM) 1:1000
PMSF (JOOmM stock) 1:100
Sodium Flouride (10M stock) 1:1'0'00.
Precision Plus Protein™ Western C™

419654)39

Sigma Stem Cell Techndloqies

mFreSR®
Matrigel
Dimethyl sulfoxide (DMSO)
....................
Lowry Assay ‘
.
'ArsenazdiU'
Alkaline phosphatase yellow liquid

Catalase assay kit
JC-1

: Gibco

Atlanta
! Gibed
Gibco

50jjg/mL Ascorbic Add
5x1Q^_M 10^25, (OHJzvjtamfnDa,________ _

Superoxide Dismutase assay kit

Catalogino/
Company
:
.<
■
. .......... >< -■
Stem CeiljTechnoldgies
j
.05850

................
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1

.

' Cayman Chemical .
Cayman Chemical;
Invitrogen ' ”
Ma c herey-Na q el'
BioRad
Thermo Scientific.
Thermo Sdentific
Sigma
Sigma '
Calbiochem
Sigma
BioRad

■
I

1
'
■

P22061
204525
D-23806
706002
707002
, T-3168
740955
. 170-8880
78833
Pl-34078
P8340
S650B
52332
201154
161-0385

Buffers
Buffers used in cell culture and assays included 10X phosphate buffer

saline (PBS) (0.2M phosphate, 1.5M NaCI, pH 7.4), 1X PBS (100mL 10X PBS,

900mL DI H2O, autoclaved), radioimmunoprecipitation assay (RIPA) buffer

(1XPBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.4 and 1:100

protease inhibitors), RNA lysis buffer (1:100 2-mercaptoethanol in RA1 lysis
buffer), 4% paraformaldehyde (PFA) (4g of paraformaldehyde in 100mL of 1X
PBS), 10X Tris-buffer saline (TBS) (30g Tris-Base, 2g KCI, 80g NaCI, pH 7.4),
1X TBS-T (100mL TBS, 900mL DI H2O, 1mL Tween 20), 10X running buffer

(30.2 Tris-Base, 188g Glycine, 10g SDS, 1L DI H2O), 1X running buffer (100mL
10X running buffer and 900mL DI H2O), 10X transfer buffer (30.2 Tris-Base,

188g Glycine, and DI H2O), and 1X transfer buffer (100mL 10X transfer buffer,

200mL methanol, 700ml DI H2O).

Table 2. Western Blot
Gel Composition.
Separation Gel'
DI-Water
YsM’ Tris-HCL"

■

•

Acryl/Bisaciylamide (30%)
10% SDS - :
10%APS............
TEMED
’
‘
Collection ,Ge| : ; .
DI Water " <
__
1,0M-Tns-HCiL Acryl/Bisacryiamide (30%)

10%'SDS: :: . •
.10%APSU‘._'-.

TEMED

'

............
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10%
5.9 mL
■3:8mL
5rnL:
150 pL
J 75 pL
: 20 pL
6%\:
2.11 mL
1.-25 mL
: 1 mL i
50 pL
I

:10pL

Table 3. Antibodies.

PotaiyMbodies ■ ' Company Catno./ SecondaryAntibodies ■■■!?'<
mouse a-paij-P-cafenii
lnvitrogbfiL :138400 goal-o-moii&HRP /
rabbit_QrpanFoxO3a Vijir. abCam “47409 ajabbitHRP ‘ :<■ inousea-TATAbinding prolein- abCam : 52703 :goal-a-mouse.HRP ; '
mouse q-dslSocalcin'.
abCaiir- 13413 goat-a-mbuse:AlexaFluor®488.

Company ■'37':
CeliSignaiingTechnology
Santa CiiEBigtedinology
CellSignatngTechnblogy
Invifrbgen.....

Catno.
7074
SC-2060
.7074
:A-11001

List of primary antibodies and corresponding secondary antibodies.

Table 4. Primer Sequence.
Primers
GAPDH
.Oct-3/4Alkaline Phosphatase
Cbfal
TWIST1
Osteopontin
Osteocalcin

Forward
GAGTCAACGGATTTGGTCGT
GfACTCCTCGGTCCCTTTCC
CCACGTCTTCACATTTGGTG
TTTGCACTGGGTCATGTGTT
ACTGGCCTGCAAAACCATA
GAAACGAGTCAGCTGGATG
GGCAGCGAGGTAGTGAAGAG

Reverse
TTGATTTTGGAGGGATCTCG
i CAAAAACCCTGGCACAAACT
AGACTGCGCCTGGTAGTTGT
TGGGTGCATTGAAAAGACTG (
TGCATTTTACCATGGGTCCT
TGAAATFGATGGGTGTGGAA
CTGGAGAGGAGCAGAACTGG

Company
Intergrated DMA Technology
Inlergrated DNA Technology
Intergrated DNA Technology
Inlergrated DNA Technology
Intergrated DNA Technology
Integrated DNA Technology
Inlergrated DNATechnology

Primers with corresponding forward and reverse sequences.
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Methods
Human Embryonic Stem Cell Cultures
H9 hESCs were obtained from WiCell. Riv4 and Riv9 were generated by

retroviral integration at UCR’s Stem Cell Core Facility and were a kind gift of Dr.
Duncan Chee Liew. All human pluripotent stem cells, were cultured in mTeSR

medium (see Table 1). hESCs were seeded in 6 well plates and kept at 37°C in
5% CO2 incubator until -70% confluency or when colonies were close to each
other (without touching). Confluency was assessed by use of an inverted
microscope. A 6 well plate was pre-coated with Matrigel for 20 minutes prior to

passage. Once confluent cultures were washed with PBS and subsequently
treated with 500pL accutase for 1 minute, the accutase was removed and cells

were suspended in the appropriate amount of mTeSR for a 1:6 passage. A cell
scraper was used to dissociate colonies into clumps and cells were distributed

evenly into 6 wells of a 6 well plate. Cultures were incubated at 37°C and 5%
CO2 and fed daily until the next passage. Passage ratio was determined by daily
monitoring of confluency. If morphological changes were detected fresh cells

were used and the old cultures were discarded.
Cryopreservation
Confluent hESCs and hiPSCs were washed with PBS and treated with
500pL accutase for 1 minute. Accutase was aspirated from the culture and cells

were suspended in 1mL of mFreSR (Table 1) with a cell scraper. Suspensions
were placed in cryovials and stored in a pre-chilled Mr. Frosty for 30 minutes at -
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20°C. Once cooled, cryovials were transferred to -80°C overnight and the

following day stored in liquid nitrogen for long term storage.
Cells were revived by immediate transfer from liquid nitrogen to 37°C
water bath. Once thawed 1mL of warm mTeSR was added to the cryovial and
the suspension was transferred to a 15mL Falcon tube with 4mL of warm
mTeSR. Cell suspension was centrifuged at 0.8g for 2.5 minutes and

subsequently the media was aspirated. Cells were resuspended in warm mTeSR

and seeded in a matrigel pre-coated 6 well plate.
Osteogenic Differentiation

Cells were grown in mTeSR until confluency, for approximately 4 days. At
confluency (designated day 0), the medium was changed to control differentiation

medium (Table 1) and cells were allowed to overgrow. On day 5 of differentiation,

the media was changed to osteogenic differentiation medium (VD3 medium).
Cultures were grown until day 30 and media was changed every 2-3days.9,39
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hESCs

hESC colonies
cultured on substrate
4 days

hESC day 0-5 of
differentiation in
control media

hESC day 5-30 of
differentiation in
VD3 media

Figure 10. Osteogenic Induction Protocol. H9 cells were cultured on
matrigel treated plates'for 4 days. Subsequently, media was changed to
control differentiation media for 5 days, day 0-5. On day 5, induction
factors, 1a,25 (OH)2 vitamin D3, |3-glycerophosphate and ascorbic acid,
were added and continued in this manner until day 30.

Tobacco Media

Smoke Solutions. MS and SS smoke solutions were kindly prepared by
Dr. Prue Talbot’s lab at the University of California Riverside, Using a University
of Kentucky analytical smoking machine, both MS and SS smoke solutions were

made in DMEM medium, and 10 cigarettes were used to achieve the
concentration of 100 puffs of smoke dissolved in 5 mL of medium (10

puffs/cigarette). Concentrations of smoke solution were measured in puff

equivalents (PE). PE is defined as the number of puffs of cigarette smoke
dissolved in 1 ml of aqueous solution (1 PE= the smoke from one puff that
dissolves; in 1 ml of mediurii). Serial dilutions were performed to achieve the PEs

desired.
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Snus Tobacco Extract. Snus tobacco extract (STE) was made at a 10%
stock solution in DMEM with 15% FBS. 10g of snus was added to 85mL of
DMEM and incubated for 2 hours at 37°C.Media was centrifuged at4500g for 10

min and supernatant was collected. The supernatant was then centrifuged at
13,000g for 1 hour and supernatant collected, pH was adjusted to 7.4. 15mL of
FBS was added to STE media and then filtered with a 0.22[jm vacuum filter
system. Snus extract was aliquoted appropriately and stored at -80°C. Serial

dilutions were performed to achieve the PEs desired

Protein Determination
For determination of protein content, cells were seeded into 48 well plates
with 5 replicates. At each collection (every 5 days beginning on day 0 until day

30) cells were washed with PBS and harvested in 300pL of RIPA buffer and

stored at -20°C.Total content of protein was assayed using the Lowry assay from
BioRad instructions. Reagent A’ was combined with 5pL of lysates and 200]jL of
reagent B was added next. After 15 minute incubation the absorbance was read

at 750nm in a Benchmark Plus microplate spectrophotometer. The protein
content of each sample was determined by a bovine serum albumin (BSA)

standard curve. Protein concentration calculations used sample values minus the
blank and multiplied by sample volume for total protein content.
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Calcium Determination

Cells were harvested as stated in protein determination protocol. Each
well (in triplicate) contained 50pL of samples and 150pL of Arsenazo 111 reagent

(DCL, Toronto, Canada).9 The change in absorbance from purple to blue was

detected at 650nm in a Benchmark Plus microplate spectrophotometer (Biorad).

Calcium content in samples was determined from an 8 point calcium standard
curve. The calcium content of each sample was standardized to its total protein

content, which was measured from the same lysate. Calcium concentration was
determined by the mean value minus the blank divided by the calibration curve.

The concentration was multiplied by the sample volume for total calcium amount,
followed by dividing it by the protein content.

Alkaline Phosphatase Activity
Cells were harvested as stated previously in protein determination
protocol. Alkaline phosphatase (ALP) activity of lysates was measured using the

pNPP method by alkaline phosphatase yellow liquid substrate system for ELISA;
reaction of each sample was done in triplicate. Each well contained 10pL of
samples with 90pL of pNPP and the p-nitrophenol produced was determined

measuring the increase in absorbance at 750nm. The ALP activity of each

sample was standardized to its total protein content. ALP activity was determined
by the Final reading minus the Initial reading divided by the time it took pnitrbphenol to produce, and then multiplied by R divided by e. R is the dilution

factor divided by the path length (0.31cm) and
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e

is the extinction coefficient

(18.45). Samples were multiplied by the sample volume and divided by the
protein concentration.

Inorganic Phosphate Determination

Cells were harvested as stated in the protein determination protocol. In the

PiPer Phosphate Assay (Molecular Probes) kit, samples were diluted in 1x
reaction buffer to yield 50 nl_. The reaction is initiated by adding 50 pL of the
Amplex Red reagent (maltose phosphorylase/maltose/glucose oxidase/HRP)
working solution. The reaction works by maltose phosphorylase converting

maltose, in the presence of inorganic phosphate (Pi) to glucosel-phosphate and
glucose. Then, glucose oxidase converted the glucose to gluconolactone and

H2O2. Horseradish peroxidase (HRP) is the catalyst, and H2O2 reacted with the

Amplex® Red reagent (10-acetyl-3,7-dihydroxyphenoxazine) to generate resorufin, whose increase in absorption was measured at 570 nm. Pi content in
samples were determined from a 7 point phosphate standard solution calibration

curve and multiplied by its dilution factor. Pi content was normalized to its protein
content.

Histochemical Analysis
Von Kossa. This method detects the deposition of calcium within the ECM.

It is based on the exchange of calcium ions (bound to phosphate) to silver ions,

which are then reduced to metallic silver in the second step of the reaction.

Mineralized deposits turn black after being exposed to light. Cells were fixed in
methanokacetone (7:3) for 20 min at -20°C, left to air dry, and washed with
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distilled water. 5% silver nitrate solution was added to the cultures until they were

covered and cultures were incubated under a strong light source (100W lamp or
direct sunlight) for 10-20 min. Cells were fixed with 5% sodium thiosulfate
solution for 2 min after washing with distilled water.

Alazarin Red. This reagent detects calcium deposits and appears redorange. It chelates with calcium phosphate crystals in the ECM. Cultures were

fixed in 4%PFA and incubated in 0.5% Alazarin red solution (2g Alazarin red,
100mL distilled water, pH 4.1-4.3) for 5 minutes at room temperature. Cultures

were washed 3X with water followed with ascending alcohol washes (70%, 80%,
90%, 100% ethanol).

Immunofluorescence. Cultures were fixed in 4% PFA for 1 hour at 4°C and

stored in PBS at 4°C. On day of staining, cultures were washed 3 times with PBS
for 5 minutes. To permeabilize cells, they were incubated in 0.1% triton-X 100 in

PBS for 15 minutes, and washed 3 times for 5 minutes with PBS. To identify
osteoblasts, the cells were blocked for 30 minutes in PBS containing 10% goat
serum and 0.5% BSA at room temperature, followed by diluting the primary
antibody (Osteocalcin) in the blocking solution overnight at 4°C. Cells were

washed 3 times the next day with PBS and appropriate secondary antibody

(Table 2) was diluted in PBS with 10% FBS and DAPI at a final concentration of

15 pM for 2 hours. Cultures were washed 3 times with PBS and visualized in a

Nikon fluorescence microscope at an excitation wavelength of 450 nm and an
emission wavelength of 490 nm.
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Ribonucleic Acid Isolation and Purification

Ribonucleic acid (RNA) was extracted using the protocol from NucleoSpin
RNAII kit. Cultures were washed once with PBS and harvested in 300pL RNA

lysis buffer and stored at -80°C. Samples were filtered and collected in
microcentrifuge tube by centrifugation at 11,000g for 1 minute. 350pL of 70%
ethanol was added and vortexed to adjust binding conditions. RNA was bound to
NucleoSpin® column, followed by desalting the silica membrane with 350pL of

membrane desalting buffer. Then, the DNA was digested with 95pL rDNase
reaction mixture incubation for 15 minutes. To wash and dry the silica

membrane, a series of three washes with RA2, RA3, and RA3 buffer was done
followed by a centrifuge at 11,000g after each wash. The RNA was eluted in

50pL of RNase-free H2O and centrifuged at 11,000g. Quantification of RNA was
determined by NanoDrop® 1000 spectrophotometer (Thermo Scientific) at

260nm. RNA samples were stored at -80°C.

Complementary Deoxyribonucleic Acid Synthesis
625 ng of RNA were reverse transcribed to form (complementary
deoxyribonucleic acid) cDNA for quantitative qPCR. 25ng of total RNA was used

as a template for cDNA synthesis with a mastermix including 5pL 5x reaction

buffer, 1.25pL 10mM deoxyribonucleotide triphosphates (dNTPs), 1.25pL
400U/pL RNase inhibitor, 0.1pL 200 U/pL reverse transcriptase, 0.1pL 3pg/pL

random primer, and 1.5pL DEPC H2O for a total of 25pL per reaction, all
transferred to PCR tubes and then PCR are machine. Tubes were heated for 10
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minutes at 25°C, then 42°C for 50 minutes, and 70°C for 15 minutes. Tubes were

stored at -20°C.

Quantitative Polymerase Chain Reaction

25ng cDNA transcripts were used for quantitative polymerase chain
reaction (qPCR). In order to quantify PCR product, SYBR green was used. SYBR
green binds to double stranded of the original template and newly formed PCR

products. SYBR green emits fluorescent signals when bound to double stranded
DNA. Aliquots of cDNA transcripts (25ng total), were added to a mastermix

including 10pL SYBR Green, 0.4pL 2.5pM forward primer, 0.4pL 2.5pM reverse
primer, and 7.2pL H2O per reaction. The reactions were setup for 10 minutes of

denaturing at 94°C (initial), followed by 40 cycles of denaturing at 94°C, and

annealing at 60°C each 45 seconds. The n-fold expression in target samples was
calculated with the AACT method by subtracting the housekeeping gene from the

gene of interest (ACT), followed by subtracting ACT from the control (AACT).
Since the increase in fluorescence is exponential, the final equation needs to be
used =POWER (2,-AACT Value) to form a linear graph.

Detection of Reactive Oxygen Species
Detection of Superoxide Anion. The LumiMax superoxide anion kit

qualitatively detects the presence of the short lived superoxide anion radicals.
Specifically, superoxide anion oxidizes luminol in the reaction that produces
photons of light that are measured with a luminometer. Cultures were harvested,

aliquoted in microcentrifuge tubes at a density of *5.0 x 105 cells in 100pL, and
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resuspended in 100pL of SOA assay medium (included with the kit). The
suspension was combined with 100pL SOA assay medium-reagent mixture
(90pL SOA assay medium, 5pL 4mM luminol, 5pL 5mM enhancer) and incubated

for 30 minutes at room temperature. The samples were transferred to

polystyrene round bottom tubes and placed in a luminometer to record light
emission (reflective light units). Samples were normalized to cell counts

determined with Cellometer cell counter (Nexcelom).
Detection of Hydrogen Peroxide. Dihydrorhodamine 123 is an uncharged

and nonfluorescent H2O2 indicator that can passively diffuse across membranes
where it is oxidized to cationic rhodamine 123 which localizes in the
mitochondria. Cells were incubated in 1pM of DHR-123 in PBS for 1h at 37°C.

Cells were washed twice with PBS and harvested in 500pL cold PBS for flow

analysis in Beckman Coulter Flow cytometer on FL1. Increased green
fluorescence intensity indicates increased ROS H2O2.

Free Scavenging Enzyme Activity

Superoxide Dismutase. Cultures were washed with PBS, harvested in
300pL of RIPA buffer, and stored at -20 °C. Once thawed, SOD assay kit was

utilized per manufacturer’s instructions. 10pL of samples were combined with
200pL of radical detector. The addition of 20pL xanthine oxidase initiated the
reaction, followed by 20 minute room temperature incubation. The absorbance
was measured at 450nm. The SOD activity of each sample was standardized to

its total protein content, which was measured from the same lysate. Absorbance
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values for each sample were compared to a 7 point SOD stock standard curve

(provided by the kit) to determine SOD activity.

Catalase. Cultures were washed with PBS, harvested in 300pL of RIPA
buffer, and stored at -20 °C. Once thawed, the catalase assay kit was utilized per

manufacturer’s instructions. To samples wells, 30pL of methanol was added,

followed by 20pL of hydrogen peroxide to initiate the reaction. After 20 minutes of

incubation, 30pL of potassium hydroxide terminated the reaction and followed by

30pL catalase purpald. Subsequently, each reaction underwent a 5 minute
incubation with 10pL catalase potassium periodate and the absorbance was read

at 540nm. Catalase activity was determined from a 7 point catalase
formaldehyde standard curve (provided by the kit). Catalase activity was
standardized to its total protein content.

Mitochondrial Membrane Potential
JC-1 (5,5',6,6'-tetrachloro-1 ,T,3,3'-tetraethylbenzimidazoyl carbocyanine

iodide) is a lipophilic cationic dye that enters the inner mitochondrial matrix in its

monomeric form when the mitochondrial membrane is polarized. When the
mitochondrion has a high mitochondrial membrane potential (A^Pm), the dye

crosses the membrane and forms J-aggregates, which appear red under UV
light If A^Pm is low, the dye remains in its monomeric form and fluoresces green.

The membrane-sensitive dye was prepared at 1x working solution in PBS from

stock solution (5mg/mL in DMSO) prior to use. Cells were harvested in
microcentrifuge tubes, centrifuged, and incubated 500pL of working solution for
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15 min in a humidified incubator at 37°C, 5% CO2. Following staining, the cells
were washed twice in PBS and resuspended in cold PBS for flow analysis in

Beckman Coulter Flow cytometer on FL1 and FL2 channels.

Fractionated Protein Isolation

In order to harvest cells for subsequent collection of fractionated protein

lysates, cell cultures were pretreated with 1mM sodium orthovanadate (stable for
30 minutes) for 30 minutes to inhibit protein tyrosine phosphatases (PTPs), which

regulates the phosphorylation state of multiple signaling molecules. This pre
treatment preserves the phosphorylation of proteins. Subsequently, cells were
washed with PBS and harvested per NE-PER Nuclear and Cytoplasmic

Extraction kit instructions. Harvested cultures were suspended in 200pL of CER I
(including protease inhibitors, sodium orthovanadate, sodium fluoride, and
PMSF) in microcentrifuge tubes. Tubes were resuspended for 15 seconds and

incubated on ice for 10 minutes. 11 pL of CER II was added to each sample,
vortexed for 5 seconds, incubated on ice for 1 minute, vortexed, and centrifuged

for 5 minutes at maximum setting (~16,000g). The supernatant is extracted and

stored at -80°C (cytoplasmic portion). The pellet is resuspended in 100pL of NER
(including protease inhibitors, sodium orthovanadate, sodium fluoride, and

PMSF) and vortexed for 15 seconds every 10 minutes for a total of 40 minutes.
Tubes were centrifuged for 10 minutes and supernatant was transferred to pre
chilled tubes (nuclear content), and stored at -80°C.
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Western Blot Analysis

Nuclear protein (20pg quantified by Lowry assay) was loaded and
separated by 10% SDS/PAGE (Table 4) in 1X running buffer at 100V for 30

minutes and 160V for 1 hour. 5pL of protein ladder (Precision Plus Protein) was
used as a guide in the process. Proteins were transferred from gels onto PVDF
membranes at 30V in transfer chamber overnight at 4°C, apparatus contains 1X

transfer buffer. Membranes were blocked in 5% milk/TBST-T for 80 min and
incubated with mouse a-pan-0-catenin, rabbit a-pan FoxO3a (abCam), and

mouse a-TATA binding protein (TBP) overnight at 4°C. The following day,

membranes were washed 3 times in TBS-T, incubated with peroxidase-

conjugated appropriate secondary antibodies for 2 hours, and washed 3 times

with TBS-T. Membranes were incubated for 5 minutes in a 1:1 ratio of
Luminol/Enhancer:Stable peroxide buffer (SuperSignal West Pico
Chemiluminescence). Blots were exposed to film from 1-15 minutes exposures,

and followed by film development.
Quantification of Band Density

To quantify the bands obtained via Western blot analysis, ImageJ software
based analysis was used (http://rsb.info.nih.gov/ij/). Under user defined area
selections, it calculated pixel value statistics. This is done by films being scanned

and saved as 8-bit grayscale TIFF files. The pixel values of each band were
corrected by subtracting a background value and then the protein of interest was

standardized to its loading control.
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Flow Cytometry
Flow cytometry is a multiple parameters analysis of a heterogeneous

population of individual cells. The flow cytometer passes cells in a single line
through a laser beam to measure the amount of light scattered (forward or

scattered) to determine the size or granularity of the cell. It can also measure
fluorescence emitted by the cells with filters including 515-545nm (FL1), 564-

601 nm (FL2), and 670 (FL3). 10,000 events were collected from stained cells
and appropriate scatter gates were set using non-stained corresponding control
cells.
Statistical Data Analysis

Each experiment was carried out in 3 or 5 replicates. The data is reported

as mean of n ± standard deviation of replicates. Comparisons were made by
one-way anova and *p < 0.05 or **p < 0.01 was considered statistically significant
from http://vassarstats.net/anova1 u.html.
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CHAPTER THREE
PREVIOUS DATA LEADING UP TO THIS STUDY

Human Embryonic Stem Cell Osteogenic Differentiation
The zur Nieden lab has previously-demonstrated osteogenic induction of

hESCs using an overgrowth approach with 1a,25 (OH)2 vitamin D3, [3-

glycerophosphate, and ascorbic acid. Assessment of osteogenesis was

measured by morphology, alkaline phosphatase (ALP) activity, calcium content,
and gene expression. Figure 11A shows mature osteoblasts on day 30.

Osteoblasts stained positive for secretion of osteocalcin (OCN) within the
extracellular matrix. OCN is a protein secreted specifically by osteoblasts. Both,
Alizarin Red S and Von Kossa stain for calcium bound to phosphate in the ECM

(Figure 11 A). Spontaneously differentiated control cultures did not stain positive
for OCN, and this held true for Alizarin and Von Kossa stains (inset). The
calcification process is easily observed due to the appearance of black

pigmentation in cultures. The black deposits in figure 6B represent calcification in
the ECM starting on day 10 of osteogenesis. Over the 30 day differentiation

protocol, the presence of calcium deposit increased.

Additionally, osteogenic cultures showed elevated ALP activity on day 6
(Figure 12A). ALP provided the inorganic phosphate necessary for calcification.
In contrast, cells grown in the absence of osteogenic factors showed minimal

change in ALP activity over the time course. Furthermore, calcium content
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increased at each timepoint (Figure 12B). Control cultures displayed no calcium

content throughout differentiation.

In order to determine developmental progression toward the osteogenic

lineage, pluripotency markers as well as genes associated with mesoderm,

osteoprogenitors and mature osteoblasts were assessed. Over the first 10 days
of osteogenic differentiation, the pluripotency marker Oct-3/4 decreased in
expression and spontaneous cultures shared the same downregulation of Oct3/4 (Figure 12C). mRNA of ALP, a crucial component in mineralization, showed a

significant upregulation of ALP expression when compared to the control (Figure
12D) and reflected this with the increase of ALP activity (Figure 12A). The

mesenchymal transcription factor TW1ST1 showed its typical pattern of an
upregulation of gene expression at the mesenchymal stage followed by a
down regulation.71 TWIST1 keeps cells in a proliferative state and the
downregulation of the gene signifies commitment towards the osteoblast lineage

(Figure 12F), whereas, the control showed a continued upregulation of TWIST1.
The bone-specific transcription factor Cbfal, osteoblast specific transcription

factor, showed a significant increase in expression as the cells matured into
osteoblasts (Figure 12E).
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Day15

Day 20

Day 25

Day 30

Differentiation of H9 hESCs was induced with 1a,25 (OH)2 vitamin
D3, (3-glycerophosphate, and ascorbic acid initiated on d5 of culture.
(A) On day 30, calcified areas were immunoreactive to an antibody
against osteocalcin: (OCN), which is unique to bone matrix; The
deposited calcium was further visualized with Alizarin: Red S (Aliz
Red S) and voh Kossa stains'. (B) Bright field images taken from
days 0-30. Data aquired by I Martinez, zur Nieden lab.

The zur Nieden lab has shown that.hESCs can be induced to differentiate into

osteoblasts without the formation of EBs. This was supported by the appearance

of mineralization and the cells positively stained for OCN. The combination of

1a,25 (OH)2 vitamin .D3i p-glycerophosphate, and ascorbic acid were added on
day 5 to osteogenic cultures, and demonstrated the transition of hESCs to mature

51

osteoblasts. This induction cocktail coupled without the formation of EBs

lessened the length of time of mineralization to 10 days instead of 30 days.39
In vitro differentiation of hESCs is potentially an alternative method for

elucidating the mechanisms of embryogenesis, development, and developmental

toxicity screening. Current in vitro methods demonstrate limitations due to length
of time of the assay and attaining reproducible results, which in turn limits the

high throughput ability. However, advances in protocols,45,72 are narrowing the

gaps between workbench and application.

hESCs make for an exciting model to study osteogenesis, as the
mineralized osteoblasts can be easily distinguished from the remainder of the

cells through their black appearance.42 This allows for the degree of

mineralization to be tracked in real time throughout the entire differentiation
period, without having to harvest the cells and kill the cultures. Specifically,

hESCs cells have shown to be a reliable method for assessment of differentiation

endpoint assays. The early onset of osteoblasts (day 10) gives an indication of
osteogenic vigor.
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Figure 12. Determination of Osteoblast Identity. Differentiation of H9 hESCs
was induced with 1 a,25 (OH)2 vitamin D3, p-glycerophosphate, and ascorbic
acid initiated on d5 of culture. (A) Measurement of alkaline phosphatase
(ALP) activity, an enzyme specifically found in osteoblast progenitors. (B)
Calcification was assessed by determining levels of matrix incorporated
calcium using Arsenazo III calcium reagent. (A-B) n=5 + SD. (C-F)
Quantitative PCR for stem cell and osteoblast specific genes. Expression of
genes of interest in osteogenic cultures was standardized to the level found
in undifferentiated cultures and normalized to GAPDH using the AACt
equation. *p<0.05 as per One-Way ANOVA, n=3±SD. Data courtesy of I.
Martinez, zur Nieden lab.
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Osteotoxicity of Tobacco Exposure
ESCs are a powerful and valuable tool to examine the teratogenic

potential of a chemical compound, zur Nieden et al. established the use of

osteotoxicity for in vitro developmental toxicity screening. This method abrogated

the need for expensive molecular assays and utilized image analysis to assess
osteotoxicity.15 The zur Nieden lab has an extensive track record in utilizing

ESCs from mouse and primate species for the detection and prediction of

skeletal teratogenicity 21,22,42,72 and the hESC model was excellent in defining
skeletal teratogenicity in the presence of tobacco products.

In order to define toxicity and skeletal teratogenicity of tobacco products,
cultures were exposed to various concentrations of MS smoke, SS smoke, or

snus (chewing tobacco) tobacco extract (STE) to determine the toxicity of

tobacco on bone. They determined that when osteogenically differentiating
hESCs were exposed to Marlboro Red 100 MS smoke solution, mineralization

continued in the Marlboro MS smoke cultures. However, calcification decreased

and cell death increased in the SS smoke treated cultures (Figure 13). STE
treated cultures displayed dose dependent inhibition of osteogenesis and
reduced cell viability in higher STE concentrations. The calcium and cytotoxicity
data, showed increased osteoblast yield and no toxic effect in increasing MS

smoke concentrations. However, they determined SS smoke was a potent

inhibitor of osteogenesis due to its cytotoxicity, increasing concentration had a
lethal effect. In contrast to the SS data, STE treated cultures displayed inhibition
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of osteogenesis at a 0.1% solution without producing lethal effect (Figure 14),

thus having a teratogenic effect.
Marlboro Red 100 and Camel snus tobacco products are popular and

easily accessed products, making them a good choice for assessing their
osteotoxicity. The ability to observe osteogenic differentiation has shown to be an

effective tool for assessing skeletal teratogenicity, due to the observations of
decreased in calcium deposits with increasing SS and STE solutions while MS
showed an increase of black deposits microscopically.

In summary, osteotoxicity screening has proven very valuable for
displaying the effects of tobacco toxicants on cell vigor. Indeed, image analysis

was able to show the effects of tobacco products on hESCs. For toxicological

screening purposes, the inhibition of mineralization (decreased black appearance

in culture) due to treatment of compounds may be an indication of developmental
toxicity, just as was described for mouse cells21,22,72, resulting in a reliable
screening method and avoiding the straining task of searching for

cardiomyocytes. Ultimately, hESCs are able to model a developing human
embryo and can be used as a screening tool for developmental toxicity under the
influence of tobacco.
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Figure 13. Treatment of Osteogenic Human Embryonic Stem Cells with Tobacco
Products. Phase contrast images show beginning toxicity at 0.1% STE, 0.1 PE
SS Marlboro Red100 while MS smoke is not toxic in any of the tested
concentrations. Figure courtesy of 1 Martinez, zur Nieden lab.
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Figure 14. Determination of Toxicity from Tobacco Exposure. Calcium
content (top) and cytotoxicity established by MTT assay (bottom),
n=5±SD. Marlboro Red 100 smoke solution was tested in
concentrations of puff equivalents (PE). MS, mainstream; SS,
sidestream. Data acquired by I Martinez, zur Nieden lab.
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CHAPTER FOUR

RESULTS

Human Embryonic Stem Cells versus Human Induced
Pluripotent Stem Cells

Since the initial generation of hiPSCs in 2006,35 much attention has been
afforded to the great promise that lies in the ability to derive pluripotent stem cells
from an individual’s own cells and elude ethical issues. Moreover, hiPSCs would
be a beneficial tool in toxicity screening by their ability to identify and predict an

individual’s (or their offspring’s) response to putative agents. However, while
hESCs and hiPSCs appear similar in the pluripotent state,35 considerable doubt

still remains about the ability of hiPSCs to differentiate towards a particular
lineage in a similar manner to hESCs.
The robustness of the ability of hiPSC lines to differentiate into bone
forming osteoblasts in vitro was determined and tested against hESC

osteogenesis. As with the derivation of hESCs, the nuclear reprogramming of

somatic cells to a pluripotent state has caused an exceptional excitement
amongst scientists. Studies elucidating the manner by which hiPSCs differentiate

will greatly contribute to the advantages of using hiPSCs in mimicking congenital
abnormalities and developmental toxicity testing.
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Experimental Design

RIV 4 and RIV9 hiPSC lines and the H9 hESC line were cultured and
osteogenically induced as previously stated in chapter 2 osteogenic induction.

Cells were initially seeded in 40 wells of a 48 well plate and 42 wells of 24 well

plates. Each cell line underwent osteogenic induction in triplicate varying from
passage to passage. Pluripotent stem cells were induced to undergo osteogenic
differentiation after the cultures had become confluent (designated day 0). On

day 5, 1a,25 (OH)2 vitamin D3, p-glycerophosphate, and ascorbic acid were
added to the osteogenic cultures (as stated in the material and methods. In vitro
culture of osteogenic differentiation was continued for 30 days. Determination of

mature osteoblasts was assessed by measurement of ALP activity, calcium
content, and qPCR for stem cell and osteoblast specific genes (Table 3). To
determine variability, differentiation was induced over three subsequent
passages of each cell line. Starting on day 0, osteogenic cultures were collected
every 5 days in RIPA buffer and RNA lysis buffer (Chapter 2). RIPA lysates were

measured for protein content, calcification, inorganic phosphate, and ALP activity

(5 biological replicates per timepoint). RNA lysates (in triplicate) were isolated
and purified, used for cDNA synthesis, and qPCR. Each cell line experiment was

setup to observe morphological differences, and to measure ALP, Ca2+, inorganic
phosphate, and gene expression. All experiments performed had 3 or 5
replicates and mean of n ± the standard deviation of the replicates are displayed.
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Results
H9, RIV4, and RIV9 cell cultures were induced to undergo osteogenic
differentiation. Each cell line exhibited black deposits, signifying mineralization,
however, the lines varied significantly in the time it took for the cultures to begin

to mineralize (Figure 15 blue box). Furthermore, the yield of black deposits varied
between each stem cell line, and the two hiPSC lines did not exhibit similar
differentiation results in relation to each other.

X
vO

R)V 4
R1V9

Figure 15. Differentiation Morphology of Cell Lines. Bright field images
show matrix mineralization. Kinetics of mineralization was found to be
different between cell lines (blue box). Bar= 500 pm.

When H9, R1V4, and RIV9 cells were assessed for osteoblast maturity

(Figure 16), calcium content determined that there was a higher yield of
mineralization on day 10 in RIV4 cultures than in H9 cultures (Figure 16A).

However, as differentiation progressed, the H9 cultures displayed a continued
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increase of mineralization throughout the protocol. As differentiation occurred in
RIV9 cultures, calcification yield reached its maximum on day 10, followed by a
decrease in calcium content. The R1V4 cultures showed a maintained amount of

calcium once calcification was established. All cultures demonstrated an increase
of ALP activity on day 5 followed by a decrease of enzymatic activity in

subsequent days (Figure 16B). However, hESC ALP activity increased on a
greater magnitude than ALP activity in either hiPSC lines. Inorganic phosphate
increased in a stepwise manner in H9 cultures while the hiPSC lines displayed

varied inorganic phosphate content (Figure 16C). Osteoblast activity (yield and
kinetics) varied between RIV4 and RIV9 cultures.
Gene expression for osteogenic regulatory proteins, as described in
chapter 3, was measured for each cell line (Figure 17). Figure 17A, shows H9

expression data, RIV9 data is viewed in Figure 17B, and RIV9 is under Figure
15C.During the first days of differentiation, the pluripotency marker Oct-4

decreased in expression in all cell lines. ALP showed an increase in expression
in H9, RIV4, and RIV9 cultures (Figure 16). H9 cultures displayed a tremendous

increase of ALP on day 5 compared to R1V4 and RIV9 lines. As the cells
matured, gene expression of TWIST1 was consistent in H9 cultures, viewed in

Chapter 1. However, RIV4 and RIV9 lines did not exhibit this pattern. Among

both hiPSC lines, they did not have the same TWIST1 expression pattern. Cbfal

increased in a stepwise manner in H9 osteogenic cultures. As was the case for
TWIST1, RIV4 cells did not display an increase in cbfal.R1V9 cells showed an
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increase on day 20, but the expression was down regulated on the next timepoint
Osteopontin (OPN) had a tremendous increase H9 cells. RIV4 and R1V9 cells did

not express OPN at the same magnitude as H9 lines. On day 15, OCN
expression remained constant, while expression in hiPSC lines fluctuated. Cbfal

increased in a stepwise manner in H9 osteogenic cultures, while RIV4 cells did
not display an increase in cbfal.
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Figure 16. Osteoblast Yield and Differentiation Kinetics Varies between Cell
Lines. (A) Ionic calcium content was assessed by determining levels of matrix:
incorporated calcium using Arsenazo III calcium reagent. Calcium content in
the cultures increased over time. (B) Measurement of alkaline phosphatase
(ALP) activity, an enzyme specifically found in osteoblast progenitors, as
determined using pNPP reagent. ALP activity was detected early in
differentiation and decreased with the onset of mineralization. (C) Inorganic
phosphate from the matrix was quantified using AmplexRed reagent. n=5 ±
SD.
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Figure 17. Osteogenic Gene Expression Varies between Cell Lines. (A-G)
H9, RIV4, and RIV9 respectively. Samples were harvested forRNA
isolation at 5 day intervals and analyzed for qPCR. Selected genes used as
markers for developmental stages between pluripotency and mature
osteoblast were measured to determine the progress of the cells in the
course of differentiation over time. Quantitative gene expression was
analyzed from the cell lines using the AACy method and compared to the
expression of the housekeeper gene GAPDH. n=3 ± SD.
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Replicate I
Replicate II
Replicate III

Figure'18. RIV4 Osteogenic Differentiation. Differentiation of RIV4
hiPSCs was induced with 1a,25(OH)2 vitamin D3, p-glycerophosphate
and ascorbic acid. Bright field images were taken from days 0-30.
Replicates indicate osteogenic differentiation from subsequent passages.
Bar= 500 pm. .

Osteogenic variability was observed in RIV4 and RIV9 lines from passage

to passage (Figure 18 and 19), Moreover, morphology and osteoblast yield
varied between the; two cell lines as well as between cell line replicates. Whereas
R1V4 cells predominately chose osteogenic: lineage commitment, RIV9 cells

formed both osteoblasts and aggregates of beating cardiomyocytes; (Figure 19

orange boxes). R1V9 cells also displayed 3D sac-like structures that contained :
beating cardiomyocytes (Figure 19).
The variability of the two hiPSC lines demonstrates that hESCs are the

gold standard and will be the tool of choice for subsequent studiesJ
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Figure 19. RIV9 Osteogenic Differentiation. Differentiation of RIV9 hiPSCs was
induced with 1a,25 (OH)2 vitamin D3, p-glycerophosphate and ascorbic acid.
Bright field images were taken from days 0-30. Replicates indicate osteogenic
differentiation from subsequent passages. Bar = 500 pm. Orange box indicates
first presence of beating cardiomyocytes.

Snus Tobacco Extract Altered Osteogenic Differentiation via

Reactive Oxygen Species
With increasing policy regulations, people are switching to harm reduction
cigarettes, including snus (chewing tobacco), “Lights” cigarettes, and electronic
cigarettes. In fact, cigarettes termed “Lights” have been shown to have

detrimental effects, if not more than conventional cigarettes, on development

processes.73
Cigarettes and their smoke combined contain over 4000 toxic chemicals

with at least 69 smoke chemicals producing cancers, proving that smoking is

harmful to smokers.1,3 We can predict that other forms of tobacco products
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possess similar chemicals and properties. Studies by Huang et al.74 have

implicated that cigarette smoke (specifically MS smoke) produces thousands of

ROS and that cigarette filters do not decrease ROS levels (Figure 20).

> H2O + O2

Proteins,
■>
Oxidative stress

lipids,DNA

Cell Death

Figure 20. Tobacco Mediated Reactive Oxygen Species. Blue box
indicates normal removal of ROS. However, tobacco products contain
ROS and can increase intracellular ROS levels, thus surpassing the
cell’s threshold for removal. Increased ROS can. result in various levels
of oxidative stress, which can detrimentally affect proteins, lipids^ and
DNA; and ultimately signal apoptosis.
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Also, ROS have a key role in bone diseases. Osteoporosis studies have
shown that ROS generation negatively associates with bone mineral density and

decreased antioxidants.75 Further studies have linked increased ROS with an

increase in bone resorption and demonstrated that osteoclasts are inhibited with
the removal of ROS.75

It is known that CatnB is necessary for osteoblast maturity by associating
with TCF/LEF.45,67 Furthermore, CatnB binds with FoxO to neutralize ROS with

the upregulation of MnSOD and catalase.62,68,69,74,76 Binding of CatnB to FoxO

prevents the interaction of CatnB and TCF/LEF, which reduces osteogenesis 45

suggesting that FoxO and TCF/LEF may compete for a limited pool of CatnB

(Figure 21). Reported findings62 suggest that age-related bone diseases, such as
osteoporosis, are potentially due to CatnB transcriptionally activating FoxO at

higher rates than TCF/LEF. Studies of FoxO and CatnB association in mouse

bones reported decreased bone formation.77 The data suggests reduced
CatnB/TCF/LEF association resulted in decreased osteoblast activity. However,
the extent of FoxO/CatnB association during embryonic skeletal development

remains unknown, as well as whether competition for CatnB is observed in
tobacco product induced oxidative stress during osteogenesis.

While there is an indication of how tobacco smoke-induced ROS affects

adult bone tissue, possibly due to increased FoxO/CatnB interaction, it remains
unknown how ROS may adversely alter embryonic skeletal development.

Because it is unethical to experiment on human embryos, it is therefore important
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to develop and employ in vitro methods to elucidate the mechanisms behind the
adverse effects of tobacco products on the developing embryo.
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mnSOD

catalase

> H2O2

- i — ■>
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Figure 21. Forkhead Box-0 and Beta-Catenin Interaction. (A)
Proposed activation of FoxO by CatnB in response to oxidative stress.
(B),Cellular defense against ROS.
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Experimental Design
To identify ROS and its role in osteogenic teratogenicity, hESCs were

osteogenically induced, and treated with non-effective (0.01%) and effective
doses (0.1%) of STE, as determined by MTT assay (chapter 5). All assays were

done on days 0, 3, 5, 7, and 12 of osteogenesis (STE treatment began on day 0).
The accumulation of O2’" and H2O2 levels was determined using LumiMax

superoxide detection kit and dihydrorhodamine-123 with subsequent FACS
analysis for H2O2 detection (n=5 ± SD). SOD and catalase activity was

determined per manufacturer’s instructions (n=3 ± SD). Cultures for SOD and

catalase activity were collected in RIPA lysates and stored at -20°C until time of

assay (chapter 2). Mitochondrial membrane potential (MMP) indicated
mitochondrial activity, and thus was a determinant of cell viability. Mitochondrial

membrane potential was measured with the JC-1 reaction and detected using

flow cytometry (n=3 ± SD). The JC-1 reaction determined if cells had a high
mitochondrial membrane potential or a low mitochondrial membrane potential.

To determine nuclear localization of CatnB and FoxO3A, H9 osteogenic
cultures were treated with non-effective and effective doses of STE and collected
for protein on days 0,3,5,7, and 12 (chapter 2). Samples were fractionated into
nuclear and cytoplasmic samples as described in chapter 2. Nuclear protein

samples were separated by SDS-PAGE, and analyzed by western blot with
CatnB and FoxO3A antibodies, and TATA binding protein as the loading control.
Activity was determined by l mageJ densitometry.
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Results

Morphological comparison of osteogenic cultures displayed osteoblast
inhibition in the STE effective dose (Figure 22), as assessed by a decrease in

black deposits. Control and non-effective dose cultures illustrated phenotypically

normal osteoblast differentiation and the onset of calcification on day 10 (not
shown). The MTT assay reflected similar results of inhibition at a 0.1% STE
concentration (Figure 14).

DayO

Day3

Day5

Day7

Dayl2

Control

Figure 22. Morphology of Snus Tobacco Extract Treated
Osteogenic Cultures. H9 cells were induced to undergo
osteogenic differentiation and treated with a non-effective
dose or effective dose of STE.
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When compared to the control and non-effective dose, H9 cells treated

with the effective dose of STE exhibited increased Of" levels on days 3, 5, and 7

(Figure 23A), while no difference between treatments was observed on day 12.
Dismutation activity was significantly decreased on days 3, 5, and 7 in the

effective dose when compared to the control and non-effective dose, and on day
12, the effective dose showed an increase in SOD activity (Figure 23B).
Comparison of the control and non-effective dose showed no significant

difference in the activity of MnSOD. H2O2 levels were significantly increased in
the effective dose at all timepoints when compared to the control (Figure 23C).
The non-effective dose displayed increased H2O2 levels on days 5, 7, and 12
when compared to the control (Figure 23C), however, the H2O2 levels were not

than the effective dose levels. The catalase activity within the effective dose

treated cells was significantly decreased during all timepoints in relation to the
control (Figure 23D). Further displaying that the control cultures showed
heightened catalase activity compared to effective dose treatment throughout
differentiation (Figure 23D). The non-effective dose exhibited a decrease in

catalase activity on days 3, 5, and 12 with no significant difference between the

two STE treatments (Figure 23D). The MMP of the control and STE treated cells
showed high mitochondrial activity on days 3, 5, and 7, while on day 12, all

treatments displayed an increase in low MMP (Figure 24).
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d

0.1% STE

RLU/1x106 cells

■ control

C
Cells positive for H2O 2 (%)

D

Figure 23. Effects of Snus Tobacco Extract on
Osteogenesis. (A,C) ROS levels were determined in H9
cultures. (B,D) Free scavenging enzyme activity. n= 3 or 5
± SD, ***P<0.001, One-Way Anova.
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Membrane Potential
8

Figure 24. Mitochondrial Membrane
Potential. n= 3 ± SD, ***P<0.01, OneWay Anova.

CatnB nuclear localization was present in each treatment at each
timepoint (Figure 25). When compared to the control, the non-effective and
effective dose showed an increase in nuclear CatnB localization on days 3 and 5.

On days 7 and 12, no significant difference in CatnB localization between the
non-effective dose and control was observed (Figure 25). However, the effective

dose displayed and upregulation of the nuclear activation of CatnB on day 7 and
12. Localization and activation of nuclear FoxO3A varied amongst treatments

(Figure 26). Nuclear localization of FoxO3A was not detected in all treatments on
day 3. The control showed no difference in nuclear FoxO3A localization on day 5

when compared to the effective dose, while the non-effective dose showed
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decreased FoxO3A nuclear localization. There was further decrease in nuclear

localization of FoxO3A in the non-effective and effective doses on day 7.
Furthermore, nuclear localization of FoxO3A in the effective dose was not
detected on day 12. There’s an inverse relationship between FoxO and TCF/LEF

and their interaction with CatnB. Western blot analysis suggests that when CatnB
signal is upregulated and FoxO is down regulated (Figure 25 and 26) then CatnB

is preferentially binding to TCF/LEF. Based on this relationship, the non-effective
dose had increased CatnB/TCF association that resulted in increased osteoblast
yield (Figure 22).
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Figure 25. Beta-Catenin Western Blot. (A) Nuclear protein samples
were probed for the presence of CatnB in samples treated with STE.
(B) Relative expression of CatnB. Control group relative signal is set
to 1.
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Figure 26. Forkhead Box-0 Western Blot. Nuclear protein
samples were probed for the presence of FoxO3A in samples
treated with STE. (B) Relative expression of FoxO. Control
group relative signal is set to 1.
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Discussion
Pluripotent Stem Cell Differentiation

We were able to observe osteogenesis (ECM calcification) of hESCs and

hiPSCs induced by the addition of 1a,25 (OH)2 vitamin D3, p-glycerophosphate,
and ascorbic acid. H9 cells showed hallmark characteristics of osteogenesis as

assessed with conventional molecular methods. Although generally capable of
osteogenic differentiation, hiPSCs did not entirely mimic H9 osteogenic
differentiation. When hESCs were compared to RIV4 and RIV9 cell lines,

molecular assays illustrated variability in osteoblast yield and differentiation
kinetics. Moreover, the presence of beating cardiomyocytes in RIV9 cultures,
indicated that hiPSCs may have the predisposition to differentiate towards a

particular lineage. Research by Narsinh et al.78 demonstrated heterogeneity
among hESCs at a molecular level. Single cell analysis of hESCs’ pluripotency

and differentiation genes illustrated variability in cellular status. They further

expanded their studies to compare hESCs to hiPSCs.78 Single cell hiPSC lines
demonstrated higher variability than hESCs of pluripotency and differentiation

regulators. Despite these differences, hESC and hiPSC colonies showed
equivalent pluripotent gene expression levels. Moreover, hiPSCs colonies do

exhibit similar pluripotency and germ layer gene expression as hESCs.78 Such

findings can suggest why a hiPSC seems predetermined to differentiate in vitro
towards a particular lineage. Specifically, the beating cardiomyocytes in culture

may be due to cells upregulating the appropriate cardiac genes.
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When differentiating hiPSCs, it is therefore necessary to determine which

line is most suitable to achieve desired differentiation outcomes. Also, FBS may
affect the potential of hiPSCs to commit towards a particular lineage. Another
possible reason for generating cardiomyocytes in our osteogenic culture was that

FBS may be affecting the osteogenic potential of the cells and pushing them

towards another lineage. Lastly, culture techniques can affect lineage

specification. Cell density can affect pluripotency and differentiation, so
passaging techniques need to be precise (though difficult) to eliminate operator

error.
In developmental toxicology screening, it is necessary to mimic in vivo
development and have reproducible results. Though the data displays

differences between hESCs and hiPSCs, this does not mean it is the end of the
road for hiPSC research. In fact, discovering the differences between hESCs and

hiPSCs provides invaluable knowledge concerning how hiPSCs can differentiate.

Further research will be required to narrow the knowledge gap between hESCs

and hiPSCs and bring hiPSCs to the forefront of patient specific toxicological

screening.
Osteotoxicity of Snus Tobacco Extract

This was the first study, to our knowledge, to investigate the effect of STEinduced ROS on osteogenic hESCs. STE generated intracellular ROS and

therefore osteogenic cultures treated with an effective dose of STE had

increased levels of ROS. Cultures treated with the effective dose also displayed
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inhibition of osteogenesis, an effect possibly due to the ROS generated from this
treatment. The increased levels of O2’“ on days 5 and 7, followed by the
decrease in SOD activity on these days suggests a blockage in the cell’s combat

machinery. Furthermore, increased H2O2 levels and decreased catalase activity

in 0.1%STE cultures suggests another blockage in the combat against ROS

removal. Within the control treatment, low ROS levels and increased free
scavenging enzyme activity, illustrated the ability of the cells to neutralize normal

intracellular ROS. The high MMP data suggests that the two STE concentrations
do not cause a stressful state within the cell, supported by the MTT assay
showing no cytotoxic effect. Additionally, the increased low MMP on day 12 may

be due to increased mitochondria in the cells. As energy demands increase in
hESCs due to differentiation, mitochondrial activity, such as OXPHOS, increases.
The data suggests that STE, like MS and SS smoke, causes embryonic

bone maldevelopment though they may use different mechanisms. Based on
calcification (reported earlier) and ROS data, it is reasonable to assume that a

developing embryo exposed to tobacco is at risk for developing a bone

abnormality or overproduction or decreased bone density, via ROS interaction.
This study and other studies56, suggest that congenital abnormalities are
potentially due to oxidative stress. In the context of lineage commitment, ROS,

generated by the mitochondrial electron transport chain in response to an
unfavorable environment, have been illustrated as a trigger of mESCs to

differentiate towards a cardiomyocyte lineage.79,80 It is the ROS at low levels that
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are involved in initiating cascades that function in cell proliferation and

differentiation.80 Furthermore, it has been reported that ROS-induced oxidative
stress, and consequently damaging mitochondria, may play a role in

neurodegenerative diseases such as Alzheimer’s disease, amyolotrophic lateral

sclerosis, and Parkinson’s disease.80 Understanding the mechanisms of
mitochondrial damage due to ROS generation holds great promise in cell
therapies for understanding developmental toxicity. This study is of great

importance in providing preliminary findings on osteotoxicity in relation to ROS.
Furthermore, it demonstrates the need for elucidating the ROS-induced activity of
mitochondria and their damaging effects on hESCs and potentially inducing

developmental toxicity. hESCs contain very few mitochondria and copies of

mitochondrial DNA (mtDNA).81 In the undifferentiated state, reliance of ESCs on
mitochondrial metabolism is diminished and dependence on this energy source

increases with differentiation of the ESCs—which also increases the supply of

mitochondria.81 Moreover, this suggests that an increased rate of aerobic
respirations would correlate with down regulation of pluripotency factors and

initiate commitment To this end, Bertoncello et al.82 were able to utilize
rhodamine 123 (Rho123), a cationic fluorescent dye, to sort out HSCs in a

heterogeneous cell population because of their low membrane potential.
Furthermore, confocal microscopy displayed a higher mitochondrial membrane
potential in differentiated cardiomyocytes than in their hESC counterparts,83 and

Spitkovsky et al.84 observed that mESCs differentiated into cardiomyocytes also
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displayed enhanced mitochondrial biogenesis during cardiogenesis. These
studies provide strong evidence that mitochondrial activity can be used as an

indicator of cell fate commitment.

We observed in the osteogenic control cultures nuclear activation of
FoxO3A which neutralized ROS levels. Studies by Essers et al. demonstrated
that activation of FoxO1, 3, and 4 regulate MnSOD and catalase as a negative

feedback loop to counteract oxidative stress, thus preventing damage.85,86 CatnB
also plays a crucial role in osteoblast differentiation. Almeida’s et al. in vivo

studies demonstrated, in mice advanced in age, decreased bone strength

associated with increased ROS levels, decreased rate of bone formation, and
increased apoptotic osteoblasts. Further, they treated osteoblast committed

mouse cells with H2O2 and determined enhanced association of CatnB and
Fox01 A.62 Such findings demonstrate the roles of FoxO, CatnB, and Wnt
signaling during age-related diseases such as osteoporosis. However, oxidative

stress observed in mesenchymal stem cell progenitors and osteoprogenitors do
not describe the interaction of CatnB and FoxO, in response to oxidative stress,

during in hESCs differentiating into osteoblasts. While, these findings correlate
with our control data, our STE treated cells do not display an upregulation of

FoxO. We show that control cultures do neutralize ROS levels through MnSOD

and catalase which are regulated by FoxO possibly activated by CatnB.
However, further increase in CatnB/TCF/LEF (Figure 27B) resulted in less

osteoblast production in the effective dose (Figure 22). Furthermore, the effective
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dose of STE did show increased ROS levels, decreased FoxO nuclear activation,

and inhibition of osteogenesis but not due to CatnB binding to FoxO. This
inhibition may be due to the misregulation of LEF/TCF and CatnB. Previous work

by Khaler et al.87 has demonstrated that LEF1 is expressed in proliferating

osteoblasts and inhibits osteoblast differentiation by downregulating osteocalcin.

Potential inhibition of osteoblast production in response to treatment with an
effective dose of STE may be due to continued expression of LEF1, a probable

consequence of excessive intracellular ROS. However, experiments are needed

to fully understand the role of TCF/LEF.
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Figure 27. Relative Beta-Catenin to FoxO. (A) Activation
of nuclear CatnB and FoxO. (B) Inverse relationship of
FoxO and TCF/LEF.
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CHAPTER FIVE

CONCLUSIONS

Tobacco Potentially Inhibits Osteogenesis via

Reactive Oxygen Species
To summarize, H9 hESCs and hiPSCs were cultured without the formation

of EBs. Colonies were able to attach to feeder-free a substrate and proliferate,

and cultures of the pluripotent cells were effectively able to undergo osteogenic
differentiation.
Osteogenic induction with the factors 1a,25 (OH)2 vitamin D3, p-

glycerophosphate, and ascorbic acid generated a higher yield of osteoblasts in

H9 cells than in human EB osteogenic differentiation. This protocol further
reduced the time to first visualize mineralization from 30 days to 10 days.

Quantified ALP activity and expression level of this enzyme, was detected early

during differentiation, and illustrated cells committing to an osteoblast fate.
Though hESCs and hiPSCs both exhibited calcium deposits in their respective

EC Ms, a hallmark of in vivo differentiation, hiPSC differentiations were not as
fruitful as hESCs differentiations. Passaging of hESCs and hiPSCs is crucial to
master because of the inability to dissociate colonies into single cells. Indeed,

passaging techniques need to be consistent for the same amount of colonies to
be seeded in each well because cell density can effect cell commitment towards

a lineage.
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Osteogenic morphologies varied between H9, RIV4 and RIV9 cell lines.

H9 and R1V4 lines underwent osteogenesis with varying yield. However, RIV9
cells lines forewent osteogenic differentiation to produce 3D sac-like structures

and beating cardiomyocytes. These observations indicated that hiPSCs have a

tendency, or are pre-programmed due to internal memory, to differentiate
towards a particular lineage. Because of their great promise for medical
research, continued efforts will be made to differentiate hiPSCs in a manner

similar to hESC differentiation.
H9 induced osteoblast differentiation is a powerful tool to examine
developmental toxicity in vitro. This abrogates the use of animal models and

difficult assessment of endpoints with the current EST protocol. Osteotoxicity was

screened with MS and SS Marlboro Red 100 smoke solutions and STE. As
assessed microscopically, osteoblast differentiation was inhibited in SS smoke

and STE, whilst MS smoke increased osteoblast yield. MTT and calcium content

further confirmed these findings. In addition, treating osteogenically induced
hESCs with STE inhibited bone formation, speculating that STE can perturb

embryonic bone development during pregnancy and result in bone
malformations.
Excessive ROS levels, produced by tobacco products, may be the cause

of the osteoblast inhibition by disrupting the Wnt/CatnB signaling pathway. ROS

does activate FoxO to neutralize normal ROS levels, while high ROS levels
showed a change in nuclear FoxO localization, and resulted in decreased
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osteoblast yield. Nuclear CatnB localization and activation needs to be further

explored but it is suspected to associate with FoxO to up reg ulate the oxidative
stress defense mechanism of the cells.

Overall, this study demonstrates a probable cause as to why embryonic

skeletal differentiation can go awry and produces birth defects.
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